Werewolf Therapeutics, Inc. (HOWL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Werewolf Therapeutics reported revenue of $0. Net income was -$60.8M, or -$1.33 per diluted share. Operating activities generated -$60.3M of cash. At fiscal year end, Werewolf Therapeutics held $69.4M in total assets against $44.6M in total liabilities, including $57.0M of cash and equivalents.
Open the full interactive Werewolf Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Werewolf Therapeutics Key Stats
| Share Price | $0.99 |
|---|---|
| Market Cap | $48.2M |
| 52-Week Range | $0.31 – $1.77 |
| Shares Outstanding | 48.6 million (basic, 2026 Q2) |
Werewolf Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$50.1M | -$56.1M | -$40.5M | -$73.6M | -$60.7M |
| Pre-Tax Income | -$50.0M | -$53.8M | -$37.4M | -$70.5M | -$60.8M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$50.0M | -$53.8M | -$37.4M | -$70.5M | -$60.8M |
| Diluted EPS | -$10.94 | -$1.86 | -$1.05 | -$1.63 | -$1.33 |
Werewolf Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$16.4M | -$8.4M | -$13.5M | $3.7M |
| Diluted EPS | -$0.36 | -$0.18 | -$0.28 | $0.08 |
Werewolf Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $157.5M | $129.3M | $134.3M | $111.0M | $57.0M |
| Current Assets | $161.1M | $140.2M | $138.4M | $113.1M | $58.6M |
| Total Assets | $179.2M | $160.2M | $174.8M | $126.9M | $69.4M |
| Current Liabilities | $11.9M | $24.0M | $19.4M | $15.2M | $36.1M |
| Total Long-Term Debt | — | — | $40.0M | $32.1M | $32.1M |
| Total Liabilities | $26.5M | $37.9M | $63.5M | $53.5M | $44.6M |
| Shareholders' Equity | $152.8M | $122.3M | $111.4M | $73.4M | $24.8M |
Werewolf Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$42.9M | -$40.6M | -$32.6M | -$56.2M | -$60.3M |
| Cash From Investing | -$498,000 | -$3.6M | -$769,000 | -$254,000 | $0 |
| Cash From Financing | $109.4M | $15.9M | $58.4M | $13.1M | $6.0M |
| Free Cash Flow | -$43.4M | -$44.2M | -$33.4M | -$56.4M | -$60.3M |
Figures from Werewolf Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Werewolf Therapeutics financials page for every line item.
Werewolf Therapeutics Company Profile
| Ticker | HOWL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001785530 |
Frequently Asked Questions
What was Werewolf Therapeutics' revenue in fiscal 2025?
Werewolf Therapeutics (HOWL) reported revenue of $0 for fiscal 2025.
What is Werewolf Therapeutics' annual revenue history?
Werewolf Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Werewolf Therapeutics' net income in fiscal 2025?
Werewolf Therapeutics reported net income of -$60.8M for fiscal 2025.
What was Werewolf Therapeutics' earnings per share (EPS) in fiscal 2025?
Werewolf Therapeutics' diluted EPS was -$1.33 for fiscal 2025 (adjusted for any later stock splits).
What was Werewolf Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Werewolf Therapeutics reported revenue of $0.
How much debt does Werewolf Therapeutics have?
Werewolf Therapeutics reported $32.1M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Werewolf Therapeutics are outstanding?
Werewolf Therapeutics reported a weighted average of 48.6 million basic shares outstanding in 2026 Q2.
What is Werewolf Therapeutics' market cap?
Based on its latest closing price, Werewolf Therapeutics (HOWL) has a market capitalization of about $48.2M.
When does Werewolf Therapeutics' fiscal year end?
Werewolf Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Werewolf Therapeutics headquartered?
Werewolf Therapeutics lists its business address in Waltham, Massachusetts in its SEC filings.